Breast Cancer Clinical Trial
Official title:
Spanish Translation and Linguistic Validation of the Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Background:
- The Common Terminology Criteria for Adverse Events (CTCAE) is a list of toxicities and
side effects that may occur when people are having cancer treatment. Doctors and nurses
use this list to describe the side effects patients experience from cancer treatment. We
have developed a questionnaire to ask people having cancer treatment directly about
common symptoms and side effects and to supply this information to their doctors and
nurses. This questionnaire is known as PRO-CTCAE and is completed by a patient.
- PRO-CTCAE was originally developed in English. Researchers want to develop a Spanish
version of the patient questionnaire. To test whether the questions are well understood
and whether it is easy to complete the questionnaire, the researchers will interview
individuals whose primary language is Spanish and who are being treated for different
types of cancer.
Objectives:
- To test a Spanish version of the PRO-CTCAE questionnaire.
Eligibility:
- Latinos at least 18 years of age who are having or have recently finished cancer treatments
and whose main language is Spanish
Design:
- Participants will complete a questionnaire in Spanish with selected questions from the
translated PRO-CTCAE. They will discuss their answers and any difficulties they might
have had in understanding or answer the questions with an interviewer, who will take
notes and record comments and suggestions.
- Literacy is not required for this study. Participants may opt to have the questions read
aloud to them by an interviewer.
This study describes a study to assess a newly created Spanish version of the National Cancer
Institute s (NCI s) patient toxicity questionnaire, the Patient Reported Outcomes Version of
the Common Terminology Criteria for Adverse Events (PRO-CTCAE), via semi-structured
interviews among Spanish-speaking patients with cancer in the United States.
Background:
The NCI s PRO-CTCAE initiative has developed and preliminarily validated a library of items
in English intended for patient self-reporting of treatment toxicity and symptoms during
participation in cancer clinical trials. These items have also been translated into Spanish,
using a methodology consistent with internationally agreed-upon guidelines for developing
global translations.
Objective:
To linguistically validate a Spanish-language version of PRO-CTCAE symptom items to assure
that they are culturally, semantically, and linguistically proficient to the native
Spanish-speaking population with cancer in the United States.
Eligibility:
Research participants must be (i) 18 years or older; (ii) able to provide informed consent;
(iii) currently undergoing systemic cancer treatment or immediately post-treatment; (iv)
speak Spanish as their primary language.
Design:
Two rounds of PRO-CTCAE questionnaire administration followed by cognitive interviews will be
conducted with Spanish speakers residing in the US. Between 40-60 interviews will be
conducted in the first round, and up to 20 additional interviews will be conducted in an
optional second round; total accrual will be 80 participants. Participating sites have been
selected to assure access to participants from a range of Spanish-speaking countries of
origin, and those with lower levels of educational attainment and acculturation.
Cognitive interviewing methodology provides an approach to determining that language
adaptations produced through forward and back translation are conceptually equivalent to the
English source document, and cross-culturally valid. Data derived from cognitive interviewing
permit a conclusion that item meanings are qualitatively equivalent after translation and
across individuals, and permit refinement, as necessary, to render terminologies and phrasing
that are culturally acceptable and relevant to the target population.
A large number of PRO-CTCAE symptom items will be evaluated in this study, and in addition,
several of the items are gender-specific. To minimize patient burden and ensure that the item
pool is uniformly evaluated relative to participant gender, education, acculturation and
country of origin, items have been distributed across four questionnaires, each matched with
a tailored interview schedule. Each participant will complete one questionnaire and
participate in one interview.
Interviewers are Bachelor- and Masters-prepared research staff who are bilingual and have
experience with cognitive interviewing in clinical research and/or cancer treatment settings.
Interview summaries will be produced in English by each interviewer; audiotapes will be
reviewed as necessary. These summaries together with relevant field notes will be assembled
into a report, and used to further refine the translated PRO-CTCAE items.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |